The content on this site is intended for healthcare professionals only
Dr Edward Garon speaks to ecancer about the role of immune checkpoint inhibitors in EGFR mutant lung cancer patients.
He explains that to date there has been great difficulty in integrating immune checkpoint inhibitors into therapy for patients who have EGFR mutations.
Dr Garon discusses a number of studies that have investigated the therapy in this setting and believes that this is an area where there isn't an ideal solution as of yet.
This programme has been supported by an unrestricted educational grant from Bristol Myers Squibb.
Understanding the remaining unmet needs in a post ASCT NDMM setting
ESMO 2024: Latest in EGFR mutated NSCLC
ASCO 2024: Lung cancer highlights
ASCO 2024: Lung cancer roundup
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Updates on lung cancer from WCLC and ESMO 2023
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC
Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1 inhibitors resistant second line metastatic NSCLC
